ETFs Holding RCPT »    RCPT Historical Stock Prices »
RCPT News Video: Wed, Jul 15, 2015, 1:34 PM — Wednesday's ETF Movers: BBH, XOP

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Receptos is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics for immune disorders. Co.'s key product candidate, RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis, an autoimmune disorder of the central nervous system, and Inflammatory Bowel Disease, which is comprised of two autoimmune, gastrointestinal inflammatory disorders: Ulcerative Colitis and Crohn's Disease. Co.'s other product candidate, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis, an immune-mediated Orphan Disease with symptoms related to esophageal dysfunction. Self directed investors in Receptos, Inc. will be interested in keeping up with all Receptos, Inc. news they can find, both RCPT news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on RCPT. At RediNews, we simplify this task by presenting both RCPT news releases originating from Receptos, Inc. itself, and RCPT news from a variety of media outlets. Visitors can browse this news online and through our RCPT RSS news feed.


RCPT News — Articles, Videos, & Press Releases

RCPT is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

FMI News

RediNews invites you to integrate our free RSS news feeds. While web portal content experience like building out an investor relations web site is a major plus when working with our RSS feeds, you don't need stock quote feed experience to begin working with something as simple as RSS — which stands for Really Simple Syndication. Although such experience could lead to some great custom market content ideas like a custom stock ticker with related news included, you don't need to be at the level of head of IR content for an IR services firm to work with our feeds. And unlike investor relations data feeds that typically carry steep licensing feeds, our RediNews RSS feeds are provided to you free of charge. To give our feeds a try, look for the RSS icon for any news page (which will look like this): .

RCPT News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.